News

UK Biotech & Life Sciences News

Follow the latest UK life sciences company news, including biotech funding rounds, pharma partnerships, product launches, clinical updates, infrastructure projects and commercial announcements.

Latest updates
Showing 109–120 of 243 stories

Oxford Nanopore Appoints Sebastian Kronmueller as Chief Business Development Officer

Oxford Nanopore Technologies has appointed Sebastian Kronmueller as Chief Business Development Officer, effective 4 January 2027. Kronmueller joins from Philips, where he was Head of Strategy and Ventures, after more than a decade at Siemens Healthineers, and will lead strategy, business development and partnerships from the US.

Silence Therapeutics Agrees $1.3B Acquisition by Merck KGaA

Silence Therapeutics has agreed to be acquired by Merck KGaA, Darmstadt, Germany for $20.00 per ADS in cash, a 130% premium to its 16 October close, valuing the company at about $1.3 billion. Merck will fund Phase 3 development of divesiran, Silence's siRNA candidate for polycythemia vera, with the deal expected to close in Q1 2027 via a UK scheme of arrangement.

IMU Biosciences Partners with UK Biobank to Profile Immune Systems of 80,000 Participants

IMU Biosciences is partnering with UK Biobank, Waters Corporation and Ultima Genomics to generate multi-omic immune profiling data from an initial 80,000 UK Biobank blood samples, with the aim of expanding to all 500,000 participants. IMU will apply its HD Immunology platform and build foundational AI models for immunology, backed by a £1.57 million UK government Sovereign AI grant.

Accession Therapeutics Appoints Martin Nicklasson as Chairman and Pierre d'Epenoux to Board

Accession Therapeutics has appointed Martin Nicklasson, Chairman of Zealand Pharma and former Chairman of Kymab, as Non-Executive Chairman, and former ImCheck Therapeutics CEO Pierre d'Epenoux as a Non-Executive Director. Nicklasson replaces co-founder Nick Cross, who steps down as Executive Chairman but remains on the board.